Search results
In the Canton of Zurich control cohort of IDH wildtype glioblastoma patients, the median progression-free survival was 4.7 months (95% CI 4.2–5.1), and the overall survival was 10.9 months (95% CI 9.1–12.7).
11 lis 2021 · Over the past decade, extensive research has been done on mutant IDH enzymes as markers of good prognosis in glioblastoma, a highly aggressive brain tumor in adults with dismal prognosis. Yet,...
15 kwi 2020 · There is growing evidence that the IDH mutation might play important roles in altering the tumour immunological microenvironment, as indicated by a suppression of tumour-infiltrating lymphocytes...
Patients with glioblastoma surviving at least 5 years from diagnosis were identified at 24 sites in Europe, US, and Australia. In patients with isocitrate dehydrogenase (IDH) wildtype tumours, prognostic factors were analysed using the Kaplan-Meier method and the Cox proportional hazards model.
19 lut 2009 · Patients with a glioblastoma carrying an IDH1 or IDH2 mutation had a median overall survival of 31 months, which was significantly longer than the 15-month survival in patients with wild-type...
15 mar 2023 · 6 Citations. Explore all metrics. Abstract. Backg round. Glioblastoma is an aggressive tumor that has a dismal prognosis even with multimodal treatment. However, some patients survive longer than expected.
8 sie 2023 · COVPRIG robustly predicts the overall survival of IDH wild-type glioblastoma and highlights METTL1 + neural-progenitor-like tumor cell in driving unfavorable outcome. Hang Ji, Fang Wang, Zhihui Liu, Yue Li, Haogeng Sun, Anqi Xiao, Huanxin Zhang, Chao You, Shaoshan Hu & Yi Liu.
